Key Takeaways
- • Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion in an all-cash deal at $53 per share, representing the largest M&A transaction in Neurocrine's history since its 1992 founding.
- • Vykat XR, Soleno's FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), generated $190.4 million in 2025 revenue including $90 million in Q4 alone, and Neurocrine projects blockbuster status with peak sales potential.
- • The acquisition strengthens Neurocrine's endocrinology portfolio alongside its $2.5 billion blockbuster Ingrezza and the recently approved Crenessity for congenital adrenal hyperplasia, positioning the company at the intersection of neuroscience and endocrine disorders.
- • PWS affects an estimated 10,000 patients in the U.S. and 300,000 to 400,000 globally; Vykat is the first FDA-approved therapy for hyperphagia in this rare genetic disorder, though addressable population is limited by the drug's side effects including hyperglycemia and edema.
- • The deal carries execution risk: recent setbacks in the PWS space include Acadia Pharmaceuticals' Phase 3 failure and Aardvark Therapeutics' voluntary pause of cardiac safety concerns, while Soleno itself faced activist short-seller scrutiny in 2025 over safety allegations that Neurocrine management dismissed as unwarranted.
Summary
Neurocrine Biosciences announced its largest acquisition to date, agreeing to buy Soleno Therapeutics for $2.9 billion in cash at $53 per share. The deal, expected to close within 90 days pending stockholder approval and regulatory clearance, represents a strategic expansion into rare endocrine disorders centered on Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. CEO Kyle Gano characterized Vykat as "all the profile aspects of a potential blockbuster in the making," signaling confidence in the drug's commercial trajectory and its fit within Neurocrine's existing portfolio.
Vykat's commercial performance supports this optimism. Since its FDA approval in March 2025 and Q2 launch, the once-daily extended-release formulation of diazoxide choline generated $190.4 million in 2025 revenue for Soleno, including $90 million in Q4 alone. This momentum swung Soleno into profitability with $20.8 million in net income for the year. The drug addresses a critical unmet need: Prader-Willi syndrome, a rare genetic neurodevelopmental disorder characterized by uncontrolled appetite, leads to morbid childhood obesity and elevated mortality risk, with approximately half of deaths occurring in patients age 18 or younger due to respiratory and cardiovascular complications. Neurocrine estimates the U.S. addressable population at roughly 10,000 PWS patients, with global estimates between 300,000 and 400,000 patients.
Neurocrine's strategic rationale centers on portfolio complementarity and commercial expertise. The company's flagship Ingrezza generated $2.5 billion in 2025 revenue from its indications in tardive dyskinesia and involuntary movements associated with Huntington's disease. Vykat will complement Crenessity, Neurocrine's recently approved rare endocrine therapy for congenital adrenal hyperplasia, allowing the company to leverage its experience commercializing treatments at the intersection of neurology and endocrinology. Samir Siddhanti, Neurocrine's vice president of business development, noted this strategic overlap, stating that Vykat's positioning between neuroscience and endocrinology represents a strong fit for Neurocrine's infrastructure.
However, the acquisition carries notable risks. The PWS therapeutic space has experienced setbacks: Acadia Pharmaceuticals halted development of its Phase 3 PWS candidate in September 2025 after failing to meet primary endpoints, while Aardvark Therapeutics voluntarily paused its Phase 3 trial in February 2026 following cardiac safety observations. Additionally, Soleno faced significant reputational damage when activist short-seller Scorpion Capital released a critical report in August 2025 alleging Vykat could cause pulmonary edema and congestive heart failure. While Neurocrine management expressed confidence in diazoxide's safety profile based on decades of clinical use, analyst Marc Goodman of Leerink Partners noted that the drug's known side effects—hyperglycemia and edema—render it unsuitable for many PWS patients, particularly those with existing obesity and diabetes comorbidities, thereby limiting addressable population penetration. Neurocrine currently has no plans to commercialize Vykat in Europe, where the drug is under regulatory review, focusing instead on maximizing the U.S. market opportunity.
Vykat's commercial performance supports this optimism. Since its FDA approval in March 2025 and Q2 launch, the once-daily extended-release formulation of diazoxide choline generated $190.4 million in 2025 revenue for Soleno, including $90 million in Q4 alone. This momentum swung Soleno into profitability with $20.8 million in net income for the year. The drug addresses a critical unmet need: Prader-Willi syndrome, a rare genetic neurodevelopmental disorder characterized by uncontrolled appetite, leads to morbid childhood obesity and elevated mortality risk, with approximately half of deaths occurring in patients age 18 or younger due to respiratory and cardiovascular complications. Neurocrine estimates the U.S. addressable population at roughly 10,000 PWS patients, with global estimates between 300,000 and 400,000 patients.
Neurocrine's strategic rationale centers on portfolio complementarity and commercial expertise. The company's flagship Ingrezza generated $2.5 billion in 2025 revenue from its indications in tardive dyskinesia and involuntary movements associated with Huntington's disease. Vykat will complement Crenessity, Neurocrine's recently approved rare endocrine therapy for congenital adrenal hyperplasia, allowing the company to leverage its experience commercializing treatments at the intersection of neurology and endocrinology. Samir Siddhanti, Neurocrine's vice president of business development, noted this strategic overlap, stating that Vykat's positioning between neuroscience and endocrinology represents a strong fit for Neurocrine's infrastructure.
However, the acquisition carries notable risks. The PWS therapeutic space has experienced setbacks: Acadia Pharmaceuticals halted development of its Phase 3 PWS candidate in September 2025 after failing to meet primary endpoints, while Aardvark Therapeutics voluntarily paused its Phase 3 trial in February 2026 following cardiac safety observations. Additionally, Soleno faced significant reputational damage when activist short-seller Scorpion Capital released a critical report in August 2025 alleging Vykat could cause pulmonary edema and congestive heart failure. While Neurocrine management expressed confidence in diazoxide's safety profile based on decades of clinical use, analyst Marc Goodman of Leerink Partners noted that the drug's known side effects—hyperglycemia and edema—render it unsuitable for many PWS patients, particularly those with existing obesity and diabetes comorbidities, thereby limiting addressable population penetration. Neurocrine currently has no plans to commercialize Vykat in Europe, where the drug is under regulatory review, focusing instead on maximizing the U.S. market opportunity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.